Discover how researchers are overcoming the limitations of the undruggable target in drug discovery using novel approaches ...

How Isomorphic Labs Is Rewriting Drug Discovery. Google DeepMind spin-off Isomorphic Labs is building an AI drug design engine that it believes can“solve” all diseases. We spoke to its Chief Technolog ...

Abstract: Deep supervised learning algorithms typically require a large volume of labeled data to achieve satisfactory performance. However, the process of collecting and labeling such data can be ...

Abstract: The timetabling problem, a well-known NP-Hard optimization challenge, spans multiple domains such as education, healthcare, sports, and transportation. Due to its computational complexity, ...

Jan 20 (Reuters) - Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday.

Jan 20 : Isomorphic Labs, which uses artificial intelligence for drug discovery, expects to have its first clinical trials by the end of 2026, founder and CEO Demis Hassabis said on Tuesday. The ...

Google DeepMind, the artificial intelligence company behind the popular AlphaFold tool, has published the next generation of the application’s protein structure prediction software. The new tool can ...